Surgical Drain Fluid MRD Detection With Patient-Specific Cutoffs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting minimal residual disease (MRD) after cancer surgery are inadequate, particularly for aggressive tumors like head and neck squamous cell carcinoma, due to the non-specificity and low concentration of biomarkers in plasma, leading to inaccurate treatment decisions.
Innovation Solution
A patient-specific cutoff for MRD is determined using the number and depth of mutations in nucleic acids from surgical drain fluid, balancing tumor mutational burden (TMB) and mutation detection coverage to enhance sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If plasma is used for biomarker detection, then accessibility is improved, but detection sensitivity and specificity deteriorate due to dilution and non-specificity
Solution Approach 1:
The invention extracts the detection target from systemic circulation (plasma) to the local surgical site (drain fluid). By taking out the biomarker detection from the diluted plasma environment and concentrating it in the proximal drain fluid, the method achieves high sensitivity and specificity while maintaining clinical accessibility through routine drain collection.
Solution Approach 2:
The invention applies local quality by shifting from systemic (plasma) to local (drain fluid) detection. The biomarker concentration and detection specificity are optimized for the local surgical site environment, where tumor-derived biomarkers are highly concentrated and directly accessible without dilution from systemic circulation.
2Quantity of substance
If conventional plasma-based liquid biopsy is used, then systemic coverage is improved, but temporal lag between biomarker release and detection increases
Solution Approach 1:
The invention performs preliminary action by collecting biomarkers at the surgical site immediately upon release, before they enter systemic circulation. The drain fluid collection captures tumor-derived biomarkers in real-time at the source, eliminating the temporal lag inherent in waiting for biomarkers to circulate systemically and appear in plasma.
3Adaptability or versatility
If high TMB is present in patient samples, then tumor heterogeneity is reflected, but false negative results increase due to lower variant allele frequency
Solution Approach 1:
The invention changes the detection parameter from plasma-based low-concentration biomarker detection to drain fluid-based high-concentration biomarker detection. This parameter change in sample source and biomarker concentration enables accurate detection even in high TMB cases where variant allele frequency is diluted, thereby maintaining detection accuracy across diverse tumor heterogeneity scenarios.
Data Source
AI summary
The present invention provides methods for detecting and predicting minimal residual disease in a subject who has undergone tumor resection surgery. Methods of the invention utilize a personalized cutoff for determining the likelihood for MRD.